Growth factor-induced therapeutic angiogenesis in the heart: Protein therapy

Cardiovascular Research

Volumn 65, Issue 3, 2005, Pages 649-655

  Annex, Brian H ^a   Simons, Michael ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Arteriogenesis; Clinical trial; Growth factors; Protein therapy

Indexed keywords

ALPHA CHEMOKINE; ANGIOPOIETIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLONY STIMULATING FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRATE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A;

ADULTHOOD; ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; EDEMA; GENE TARGETING; HEART; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; NEOVASCULARIZATION (PATHOLOGY); NEUROLOGICAL COMPLICATION; NIGHTMARE; NONHUMAN; OCCULT CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTLESSNESS; REVASCULARIZATION; REVIEW; SIDE EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TUMOR GROWTH; VIRAL GENE THERAPY; VIVID DREAM;

ADULT; ANGIOGENESIS INDUCING AGENTS; CLINICAL TRIALS; CORONARY CIRCULATION; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 12344288420     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.09.004     Document Type: Review

References (58)

1. American Heart Association Heart Disease and Stroke Statistics - 2003 Update 2003 American Heart Association Dallas
2. D. Mukherjee, K. Comella, D.L. Bhatt, M.T. Roe, V. Patel, and S.G. Ellis Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization Am. Heart J. 142 2001 72 74
3. H.C. Lowe, S.N. Oesterle, K.L. He, B.D. Macneill, and D. Burkhoff Outcomes following percutaneous coronary intervention in patients previously considered "without option": a subgroup analysis of the PACIFIC Trial J. Interv. Cardiol. 17 2004 87 91
4. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat. Med. 6 2000 389 395
5. C.W. Pugh, and P.J. Ratcliffe Regulation of angiogenesis by hypoxia: role of the HIF system Nat. Med. 9 2003 677 684
6. A. Helisch, and W. Schaper Arteriogenesis: the development and growth of collateral arteries Microcirculation 10 2003 83 97
7. E.D. de Muinck, and M. Simons Re-evaluating therapeutic neovascularization J. Mol. Cell. Cardiol. 36 2004 25 32
8. I. Buschmann, and W. Schaper The pathophysiology of the collateral circulation (arteriogenesis) J. Pathol. 190 2000 338 342
9. W. Schaper, and D. Scholz Factors regulating arteriogenesis Arterioscler. Thromb. Vasc. Biol. 23 2003 1143 1151
10. T. Asahara, H. Masuda, T. Takahashi, C. Kalka, C. Pastore, and M. Silver Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization Circ. Res. 85 1999 221 228
11. A. Luttun, and P. Carmeliet De novo vasculogenesis in the heart Cardiovasc. Res. 58 2003 378 389
12. T. Ziegelhoeffer, B. Fernandez, S. Kostin, M. Heil, R. Voswinckel, and A. Helisch Bone marrow-derived cells do not incorporate into the adult growing vasculature Circ. Res. 94 2004 230 238
13. P. Carmeliet Angiogenesis in health and disease Nat. Med. 9 2003 653 660
14. W. Zheng, EA. Seftor, CJ. Meininger, MJ. Hendrix, and RJ. Tomanek Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta Am. J. Physiol, Heart Circ. Physiol. 280 2001 H909 H917
15. L. Lei, R. Zhou, W. Zheng, LP. Christensen, RM. Weiss, and RJ. Tomanek Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart Circulation 110 2004 796 802
16. S.J. Kim, C. Depre, and S.F. Vatner Novel mechanisms mediating stunned myocardium Heart Fail. Rev. 8 2003 143 153
17. P. Carmeliet, Y.S. Ng, D. Nuyens, G. Theilmeier, K. Brusselmans, and I. Cornelissen Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 Nat. Med. 5 1999 495 502
18. Y. Huang, R.P. Hickey, J.L. Yeh, D. Liu, A. Dadak, and L.H. Young Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart FASEB J. 18 2004 1138 1140
19. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676
20. Z. Poltorak, T. Cohen, R. Sivan, Y. Kandelis, G. Spira, and I. Vlodavsky VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix J. Biol. Chem. 272 1997 7151 7158
21. T.T. Rissanen, J.E. Markkanen, M. Gruchala, T. Heikura, A. Puranen, and M.I. Kettunen VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses Circ. Res. 92 2003 1098 1106
22. T. Matsumoto, and L. Claesson-Welsh VEGF receptor signal transduction Sci. STKE 2001 2001 RE21
23. I. Zachary, and G. Gliki Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family Cardiovasc. Res. 49 2001 568 581
24. A. Ishida, J. Murray, Y. Saito, C. Kanthou, O. Benzakour, and M. Shibuya Expression of vascular endothelial growth factor receptors in smooth muscle cells J. Cell. Physiol. 188 2001 359 368
25. M. Lohela, A. Saaristo, T. Veikkola, and K. Alitalo Lymphangiogenic growth factors, receptors and therapies Thromb. Haemost. 90 2003 167 184
26. P. Auguste, S. Javerzat, and A. Bikfalvi Regulation of vascular development by fibroblast growth factors Cell Tissue Res. 314 2003 157 166
27. D.M. Ornitz, and N. Itoh Fibroblast growth factors Genome Biol. 2 2001 reviews3005.1 reviews3005.12
28. C.J. Powers, S.W. McLeskey, and A. Wellstein Fibroblast growth factors, their receptors and signaling Endocr. Relat. Cancer 7 2000 165 197
29. A. Horowitz, E. Tkachenko, and M. Simons Fibroblast growth factor-specific modulation of cellular response by syndecan-4 J. Cell Biol. 157 2002 715 725
30. R. Khurana, and M. Simons Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease Trends Cardiovasc. Med. 13 2003 116 122
31. R. Cao, E. Brakenhielm, R. Pawliuk, D. Wariaro, M.J. Post, and E. Wahlberg Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 Nat. Med. 9 2003 604 613
32. M. Simons, and J.A. Ware Therapeutic angiogenesis in cardiovascular disease Nat. Rev., Drug Discov. 2 2003 863 871
33. T. Couffinhal, M. Silver, M. Kearney, A. Sullivan, B. Witzenbichler, and M. Magner Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/- mice Circulation 99 1999 3188 3198
34. Y. Dor, V. Djonov, R. Abramovitch, A. Itin, G.I. Fishman, and P. Carmeliet Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy EMBO J. 21 2002 1939 1947
35. M.J. Post, R. Laham, F.W. Sellke, and M. Simons Therapeutic angiogenesis in cardiology using protein formulations Cardiovasc. Res. 49 2001 522 531
36. G.C. Hughes, M.J. Post, M. Simons, and B.H. Annex Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis J. Appl. Physiol. 94 2003 1689 1701
37. S. Yla-Herttuala, and K. Alitalo Gene transfer as a tool to induce therapeutic vascular growth Nat. Med. 9 2003 694 701
38. M. Simons, and M.J. Post Therapeutic angiogenesis E.J. Topol Textbook of Interventional Cardiology 2002 New York Lippincot
39. M.J. Wright, L.M. Wightman, D.S. Latchman, and M.S. Marber. In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo Gene Ther. 8 2001 1833 1839
40. M.J. Wright, L.M. Wightman, C. Lilley, M. de Alwis, S.L. Hart, and A. Miller In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors Basic Res. Cardiol. 96 2001 227 236
41. B. Schumacher, P. Pecher, B.U. von Specht, and T. Stegmann Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease Circulation 97 1998 645 650
42. R.J. Laham, F.W. Sellke, E.R. Edelman, J.D. Pearlman, J.A. Ware, and D.L. Brown Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial Circulation 100 1999 1865 1871
43. M. Ruel, R.J. Laham, J.A. Parker, M.J. Post, J.A. Ware, and M. Simons Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein J. Thorac Cardiovasc. Surg. 124 2002 28 34
44. R.J. Laham, N.A. Chronos, M. Pike, M. Leimbach, J.E. Udelson, and J.D. Pearlman Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study J. Am. Coll. Cardiol. 36 2000 2132 2139
45. E.F. Unger, L. Goncalves, S.E. Epstein, E.Y. Chew, C.B. Trapnell, and R.O. Cannon 3rd Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris Am. J. Cardiol. 85 2000 1414 1419
46. J.E. Udelson, V. Dilsizian, R.J. Laham, N. Chronos, J. Vansant, and M. Blais Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease Circulation 102 2000 1605 1610
47. M. Simons, B.H. Annex, R.J. Laham, N. Kleiman, T. Henry, and H. Dauerman Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial Circulation 105 2002 788 793
48. R.C. Hendel, T.D. Henry, K. Rocha-Singh, J.M. Isner, D.J. Kereiakes, and F.J. Giordan Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect Circulation 101 2000 118 121
49. T.D. Henry, K. Rocha-Singh, J.M. Isner, D.J. Kereiakes, F.J. Giordano, and M. Simons Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease Am. Heart J. 142 2001 872 880
50. T.D. Henry, B.H. Annex, GR. McKendall, M.A. Azrin, J.J. Lopez, and F.J. Giordano The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis Circulation 107 2003 1359 1365
51. C. Seiler, T. Pohl, K. Wustmann, D. Hutter, P.A. Nicolet, and S. Windecker Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study Circulation 104 2001 2012 2017
52. I. Buschmann, M. Heil, M. Jost, and W. Schaper Influence of inflammatory cytokines on arteriogenesis Microcirculation 10 2003 371 379
53. H.J. Kang, H.S. Kim, S.Y. Zhang, K.W. Park, H.J. Cho, and B.K. Koo Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial Lancet 363 2004 751 756
54. H. Matsubara Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine therapy Lancet 363 2004 746 747
55. J.D. Pearlman, R.J. Laham, M. Post, T. Leiner, and M. Simons Medical imaging techniques in the evaluation of strategies for therapeutic angiogenesis Curr. Pharm. Des. 8 2002 1467 1496
56. D. Burkhoff, J.W. Jones, and L.C. Becker Variability of myocardial perfusion defects assessed by thallium-201 scintigraphy in patients with coronary artery disease not amenable to angioplasty or bypass surgery J. Am. Coll. Cardiol. 38 2001 1033 1039
57. J. Barkhausen, P. Hunold, M. Jochims, and J.F. Debatin Imaging of myocardial perfusion with magnetic resonance J. Magn. Reson. Imaging 19 2004 750 757
58. N.M. Wilke, A.G. Zenovich, M. Jerosch-Herold, and T.D. Henry Cardiac magnetic resonance imaging for the assessment of myocardial angiogenesis Curr. Interv. Cardiol. Rep. 3 2001 205 212